Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model

Amino Acids

Volumn 43, Issue 3, 2012, Pages 1359-1367

  Minelli, Alba ^a   Conte, C ^a   Cacciatore, I ^b   Cornacchia, C ^b   Pinnen, F ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

LD GPE; MPTP; NF B; Nrf2; PD animal model

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLYCYLPROLYLGLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVODOPA; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TRANSCRIPTION FACTOR NRF2; TRIPEPTIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN DAMAGE; BRAIN TISSUE; CONTROLLED STUDY; COVALENT BOND; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME REGULATION; GENE CONTROL; GLIA CELL; INFLAMMATION; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PLASMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; HEME OXYGENASE-1; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OLIGOPEPTIDES; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PARKINSONIA; RATTUS;

EID: 84867044861     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1210-x     Document Type: Article

References (43)

1. Aguado-Llera D, Martín-Martínez M, García- López MT, Arilla- Ferreiro E, Barrios V (2004) Gly-Pro-Glu protects beta-amyloidinduced somatostatin depletion in the rat cortex. Neuroreport 15:1979-1982 (Pubitemid 39180625)
2. Alexi T, Hughes PE, van Roon-Mom WM, Faull RL, Williams CE, Clark RG, Gluckman PD (1999) The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Exp Neurol 159:84-97 (Pubitemid 29444905)
3. Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Yang L, Beal MF, Roth RH, Matthews RT, Horvath TL (2005) Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J Neurosci 25:184-191 (Pubitemid 40110779)
4. Baker AM, Batchelor DC, Thomas GB, Wen JY, Rafiee M, Lin H, Guan J (2005) Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 39:81-87 (Pubitemid 40327000)
5. Batchelor DC, Lin H, Wen JY, Keven C, Van Zijl PL, Breier BH, Gluckman PD, Thomas GB (2003) Pharmacokinetics of glycine- proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal Biochem 323:156-163 (Pubitemid 37491137)
6. Bezard E, Dovero S, Bioulac B, Gross CE (1997a) Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 148:288-292 (Pubitemid 127445136)
7. Bezard E, Dovero S, Bioulac B, Gross CE (1997b) Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett 234:47-50 (Pubitemid 27435966)
8. Bodor N, Sloan KB, Higuchi T, Sasahara K (1977) Improved delivery through biological membranes. 4 Prodrugs of L-dopa. J Med Chem 20:1435-1445 (Pubitemid 8209552)
9. Branco DM, Arduino DM, Esteves AR, Silva DF, Cardoso SM, Oliveira CR (2010) Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci 2:17. doi:10.3389/fnagi.2010.00017
10. Brigelius-Flohe R, Flohé L (2011) Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal. doi:10.1089/ars.2010.3534
11. Brimble MA, Trotter NS, Harris PW, Sieg F (2005) Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE). Bioorg Med Chem 13:519-532 (Pubitemid 39642934)
12. Burgos-Ramos E, Martos-Moreno GA, López MG,Herranz R, Aguado- Llera D, Egea J, Frechilla D, Cenarruzabeitia E, León R, Arilla- Ferreiro E, Argente J, Barrios V (2009) The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloidinduced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem 109:360-370
13. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci USA 106:2933-2938
14. Dahmer J, Whitesides GM (1989) Kinetic resolution of unnatural and rarely occurring amino acids: enantioselective hydrolysis of N-acyl amino acids catalyzed by acylase I. J Am Soc 111:6354-6364
15. Du F, Qian ZM, Zhu L, Wu XM, Yung WH, Tsim TY, Ke Y (2009) L-dopa neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PLoS One 4:e4593
16. Guan J, Waldvogel HJ, Faull RL, Gluckman PD, Williams CE (1999) The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 89:649-659 (Pubitemid 29070993)
17. Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P (2000) N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 859:286-292 (Pubitemid 30136100)
18. Guan J, Thomas GB, Lin H, Mathai S, Bachelor DC, George S, Gluckman PD (2004) Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline- glutamate (GPE) following intravenous infusion in hypoxic- ischemic adult rats. Neuropharmacology 47:892-903 (Pubitemid 39440983)
19. Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A, Kubo S, Mochizuki H (2009) Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15:S35-S38
20. Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A (2010) Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5:e11838
21. Jadhav A, Torlakovic E, Ndisang JF (2008) Interaction among heme oxygenase, nuclear factor-kappaB, and transcription activating factors in cardiac hypertrophy in hypertension. Hypertension 52:910-917
22. Jung KH, Hong SW, Zheng HM, Lee HS, Lee H, Lee DH, Lee SY, Hong SS (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 98:8798-8803
23. Jung KH, Hong SW, Zheng HM, Lee HS, Lee H, Lee DH, Lee SY, Hong SS (2010) Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res 48:239-250
24. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M (2001) Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6:857-868 (Pubitemid 33019739)
25. Krishnamurthi R, Stott S, Maingay M, Faull RL, McCarthy D, Gluckman P, Guan J (2004) N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 15:1601-1604 (Pubitemid 38971179)
26. Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat Med 8:240-246
27. Minelli A, Conte C, Grottelli S, Bellezza I, Emiliani C, Bolaños JP (2009) Cyclo(His-Pro) up-regulates heme oxygenase 1 via activation of Nrf2-ARE signalling. J Neurochem 11:956-966
28. Minelli A, Conte C, Prudenzi E, Cacciatore I, Cornacchia C, Taha E, Pinnen F (2010) N-acetyl-L-methionyl-L-dopa-methyl ester as a dual acting drug that relieves L-dopa-induced oxidative toxicity. Free Radic Biol Med 49:31-39
29. Nagatsua T, Sawadab M (2009) L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 15(Suppl 1):S3-S8
30. Pinnen F, Cacciatore I, Cornacchia C, Sozio P, Iannitelli A, Costa M, Pecci L, Nasuti C, Cantalamessa F, Di Stefano A (2007) Synthesis and study of L-dopa-glutathione codrugs as new anti- Parkinson agents with free radical scavenging properties. J Med Chem 50:2506-2510
31. Pinnen F, Cacciatore I, Cornacchia C, Sozio P, Cerasa LS, Iannitelli A, Nasuti C, Cantalamessa F, Sekar D, Gabbianelli R, Falcioni ML, Di Stefano A (2009) Codrugs linking L-dopa and sulfurcontaining antioxidants: new pharmacological tools against Parkinson's disease. J Med Chem 52:559-563
32. Rahman I, Kode A, Biswas SK (2006) Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 1:3159-3165
33. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58:588-598
34. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2008) Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflammaging. Ageing Res Rev 7:83-105 (Pubitemid 351418294)
35. Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M, Hakansson LN, Civalero I, Nordberg A (1989) Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Biochem Biophys Res Commun 165:766-771 (Pubitemid 20025588)
36. Saura J, Curatolo L, Williams CE, Gatti S, Benatti L, Peeters C, Guan J, Dragunow M, Post C, Faull RL, Gluckman PD, Skinner SJ (1999) Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. Neuroreport 10:161-164 (Pubitemid 29090500)
37. Schapira AH (2009) Etiology and pathogenesis of Parkinson disease. Neurol Clin 27:583-603
38. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282 (Pubitemid 33141302)
39. Shapira S, Mathai S, Zhang R, Guan J (2009) Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsèhere induced embolic damage in young adult and aged rats. Neurosci Lett 454:53-57
40. Sizonenko SV, Sirimanne ES, Williams CE, Gluckman PD (2001) Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury. Brain Res 922:42-50 (Pubitemid 33152843)
41. Weiner WJ (2006) Levodopa-toxic or neuroprotective? Nat Clin Pract Neurol 2:518-519
42. Zhao X, Liu SJ, Zhang J, Strong R, Aronowski J, Grotta JC (2005) Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke 36:129-134 (Pubitemid 40054188)
43. Zou J, Crews F (2006) CREB and NF-kappaB transcription factors regulate sensitivity to excitotoxic and oxidative stress induced neuronal cell death. Cell Mol Neurobiol 26:385-405